Clinical Trial Update: A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating CC-98633, a BCMA-targeted CAR T-cell therapy, in relapsed and/or refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CC-98633

Snippet

Sponsor: Juno Therapeutics, a Subsidiary of Celgene | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED